1. Scrip
  2. >>Business
  3. >>Strategy

Kaiser Permanente's Dual Purpose Funding Venture

 
• By Wendy Diller

Kaiser Permanente Ventures has been carving out an unusual niche for itself in the straightforward world of corporate venture funding. While return on investment is of utmost importance to most venture funds, KP's mission is broader. Under the direction of Chris Stenzel, its goal is to not only achieve economic success but to improve quality of services and offer new ways of delivering care to members and communities.

In the three years since the giant HMO Kaiser Permanente got the entrepreneurial bug, its venture group, Kaiser Permanente Ventures, has been carving out an unusual niche for itself in the straightforward world of corporate venture funding (see "Kaiser Permanente Gets the Venture Bug,"START-UP, March 1998 [A#1998900046). While return on investment is the top priority for most venture funds, KP's mission is broader. Under the direction of Chris Stenzel, VP, its goal is not only to achieve economic success but to improve quality of services and offer new ways of delivering care to members and communities.

KP's venture group engages in three types of activities, according to Stenzel. First, it looks at business development opportunities to...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from Strategy

Asia Deal Watch: Lupin Picks Sandoz To Market Lucentis Biosimilar In Parts Of EU And Asia

 
• By Joseph Haas, Sushmita Panda, Xu Hu, Vibha Ravi, and Manas Mishra

Also deals involving Xspray/Handa, Fosun/Expedition, Kaken/Astria, Orchid/Allecra, Sanofi/Visirna, KKR/Healthcare Royalty Partners, Viridian/Kissei, Sandoz/Evotec, Dx&Vx, Dr. Falk/Allianthera, Madrigal/CSPC and Lilly/LTZ.

Lupin Confident Of US Growth On Tariff Mitigation, Rides High On Tolvaptan

 
• By Vibha Ravi

Lupin is hoping moves like intellectual property transfer for some products to the US will help mitigate the tariff impact even as it counts on growth from planned launches of GLP-1s and biosimilars while riding high on tolvaptan launched in Q1.

Sanofi’s Sarclisa Wins Another EU Multiple Myeloma Nod In Its Unequal Battle With J&J’s Darzalex

 
• By Sushmita Panda

The French drugmaker's anti-CD38 antibody has racked up another approval in first-line multiple myeloma, but it marks a small victory while the company develops a subcutaneous version to help level the field with J&J’s Darzalex.

More Players, Better Pricing, Tough Equity Market: Royalty Deals Go Mainstream

 
• By Manas Mishra

Royalty deals are on track for another blowout year, but it’s not only because of a depressed biotech market. Large investment firms such as KKR are taking note.

More from Business

Japan Results Roundup: Reduced Forex Impact, Uncertain US Tariff Outlook

 
• By Lisa Takagi

Most major Japanese firms report generally positive fiscal first quarter results, led by mainstay growth and despite lower currency effects. But the future impact of any US pharma tariffs remains an overhang.

In Brief: Bayer Commits Up To $1.3bn For Kumquat’s KRAS G12D Inhibitor

 
• By Mary Jo Laffler

Deal Snapshot: Bayer will take over development of the asset once Kumquat completes a Phase Ia clinical trial, but the biotech firm may opt in to share US profits and losses.

S&E In Brief: Launch Updates And Political Headwinds

 
• By Sushmita Panda

Madrigal and Syndax update investors on their key launches, while Merck KGaA weighs in on the possibility of direct-to-consumer sales in the US.